Skip to main content
PO

Peter O’Donnell

Brussels Correspondent, APM Health Europe

APM Health Europe

p***@apmhealtheurope.com Upgrade
Pro only
Ile-de-France, France

About

Brussels correspondent APM, Europe columnist ACT

Industries

Recent Article

Efficacy and safety of pembrolizumab in patients with advanced urothelial carcinoma deemed potentially ineligible for platinum‐containing chemotherapy: Post hoc analysis of KEYNOTE‐052 and LEAP‐011

Upgrade for article links
95 total articles published · Brussels Correspondent